Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Oct 4;9(10):e002505. doi: 10.1136/jitc-2021-002505

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Identification of a CXCL12-associated CD14+ CD15 monocytic precursor cell type and myeloid markers associated with tissue response to NOX-A12 treatment. (A) Schematics of the virtual thin section overlay workflow applied to identify the CD14⁺CD15⁺CXCL12⁺ cells in tissue biopsies. Comparative immune landscape in tissues at the onset of treatment with NOX-A12 and impact of NOX-A12 in the immune landscape in responders and non-responders (left) and the relative changes in CD14⁺CD15⁺ cell density at day 14 (right). (B) Dot plot illustrating the concentration of CXCL12 in the liver metastasis at the onset of treatment, as well as its correlation with the density of CX14⁺CD15⁺ cells in the corresponding tissues at the same time point. (C) Density of CD11b+ cells at treatment onset and under treatment. (D) Density of cells positive for arginase and iNOS immunostains before the onset of therapy, in responders and non-responder (left) and relative changes under treatment (right).